RESUMEN
Objective:To investigate and compare the influence of systemic inflammation score(SIS) and modified glasgow prognostic score(mGPS) on patients undergoing radical surgery for gallbladder cancer.Methods:A cohort study was used to collect the clinical data of total 50 patients with gallbladder cancer who underwent radical surgery in Zhongda Hospital Affiliated to Southeast University from March 2010 to March 2020. Survival analysis was utilized to assess the impact of SIS and mGPS for prognosis.The predictive accuracy of each score was compared by means of subgroup analysis and time dependent receiver operating characteristics analysis.Measurement data with normal distribution were expressed as mean±standard deviation( ± s), and t test was used for comparison between groups. Count data were expressed as cases and percentages (%), and chi-square test was used for comparison between groups. Results:The 1-, 2-and 3-year survival rate of 50 gallbladder cancer patients undergoing radical surgery were 76%, 55%, 37.6%. Cox multivariate analysis showed SIS score ( HR=2.072, P=0.014) was independent prognostic risk factor; Time dependent ROC curve analysis found that the area under the SIS curve was significantly greater than the mGPS at postoperative 1 year (0.748 vs 0.603, P=0.024); Subgroup analysis found in advanced patients, SIS score was statistically significant compared with mGPS ( P=0.03). Conclusions:SIS is superior to mGPS for predicting OS in patients with gallbladder cancer who underwent radical surgery, and SIS is an independent risk factors for prognosis of patients with gallbladder cancer.
RESUMEN
Objective@#To study the predictive and prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) on the effect of neoadjuvant chemotherapy for advanced gastric cancer.@*Methods@#117 patients with advanced gastric cancer received neoadjuvant chemotherapy with SOX (oxaliplatin+ S1) or mFOLFOX 6(oxaliplatin+ CF+ 5-FU) regimen. HS-mGPS was calculated according to blood C-reactive protein (CRP) concentration and serum albumin (ALB) level. The correlation between HS-mGPS and clinicopathological characteristics was determined and the predictors of survival were analyzed.@*Results@#117 patients with stage ⅡB (43 cases), stage Ⅲ (60), and stage Ⅳ (14) received preoperative neoadjuvant chemotherapy. The overall response rate of neoadjuvant chemotherapy was 61.5%(72/117), and the tumor control rate was 88.0% (103/117), with a pathological response rate of 91.5% (107/117). The R0 resection rate was 81.2% (95/117). The median disease-free survival (DFS) was 21.0 (95% CI 6.4-35.6) months. The median overall survival (OS) was 39.0 (95% CI 21.4-56.6) months. Higher HS-mGPS was associated with higher T stage, local lymph-node metastasis, distant metastasis, lower chemotherapy overall response rate and lower pathological response rate (all P<0.05). The univariate analysis and multivariate analysis showed that higher HS-mGPS, presence of local lymph-node metastasis and non R0 resection were associated with poorer DFS and OS (P<0.05).@*Conclusion@#HS-mGPS can be used to predict the benefits of neoadjuvant chemotherapy and as an independent prognostic factor for survival in patients with advanced gastric cancer.
RESUMEN
PURPOSE: The modified Glasgow Prognostic Score (mGPS) consisting of serum C-reactive protein and albumin levels, shows significant prognostic value in several types of tumors. We evaluated the prognostic significance of mGPS in 285 patients with diffuse large B cell lymphoma (DLBCL), retrospectively. MATERIALS AND METHODS: According to mGPS classification, 204 patients (71.5%) had an mGPS of 0, 57 (20%) had an mGPS of 1, and 24 (8.5%) had an mGPS of 2. RESULTS: Our study found that high mGPS were associated with poor prognostic factors including older age, extranodal involvement, advanced disease stage, unfavorable International Prognostic Index scores, and the presence of B symptoms. The complete response (CR) rate after 3 cycles of R-CHOP chemotherapy was higher in patients with mGPS of 0 (53.8%) compared to those with mGPS of 1 (33.3%) or 2 (25.0%) (p=0.001). Patients with mGPS of 0 had significantly better overall survival (OS) than those with mGPS=1 and those with mGPS=2 (p=0.036). Multivariate analyses revealed that the GPS score was a prognostic factor for the CR rate of 3 cycle R-CHOP therapy (p=0.044) as well as OS (p=0.037). CONCLUSION: mGPS can be considered a potential prognostic factor that may predict early responses to R-CHOP therapy in DLBCL patients.